scholarly journals Fluticasone Propionate, 100 µg bid, Using a Non-CFC Propellant, HFA 134a, in Asthmatic Children

2003 ◽  
Vol 10 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Brian Lyttle ◽  
John Gillies ◽  
Maarja Panov ◽  
Andrzej Emeryk ◽  
Claire Wixon
Keyword(s):  
Fluticasone Propionate ◽  
Treatment Period ◽  
Peak Expiratory Flow ◽  
Dose Inhaler ◽  
Double Blind ◽  
Asthmatic Patients ◽  
Morning Peak ◽  
Morning Peak Expiratory Flow ◽  
Equivalent Efficacy ◽  
Expiratory Flow

BACKGROUND: Secondary to phasing out chlorofluorocarbons (CFCs), the fluticasone propionate (FP) pressurized metered-dose inhaler has been formulated in a nonozone-depleting propellant, hydrofluoralkane (HFA) 134a.OBJECTIVES: To demonstrate equivalent efficacy and safety of FP 200 µg daily propelled by HFA 134a to FP 200 µg daily propelled by CFCs 11 and 12 over a four-week treatment period in pediatric asthmatic patients.METHODS: The study was multinational, randomized, double blind and of parallel group design. Eligible patients aged 16 years and younger were steroid naive or receiving 500 µg/day or less of beclomethasone dipropionate, budesonide or flunisolide, or 250 µg/day or less of inhaled FP. The primary efficacy variable was mean morning peak expiratory flow with equivalence determined if the 90% CIs for the treatment differences between groups were within ±15 L/min.RESULTS: Three hundred fifteen patients (mean age 9.3±2.8 years) were randomly assigned; 158 patients received FP HFA 134a and 157 patients received FP CFC. Over the four-week treatment period, mean morning peak expiratory flow increased from baseline in both groups (14 L/min and 17 L/min, respectively), with a mean treatment difference of -2 L/min. Equivalence was demonstrated between the groups (90% CI -6 to +3 L/min; P=0.589). Both formulations were well tolerated with no serious drug-related events.CCONCLUSIONS: FP propelled by HFA 134a has equivalent efficacy and comparable safety to FP propelled by CFC propellants at a microgram equivalent dose in pediatric asthmatic patients.

scholarly journals Rapid onset of effect of benralizumab on morning peak expiratory flow in severe, uncontrolled asthma

2019 ◽  
Vol 122 (5) ◽  
pp. 478-485 ◽  
Author(s):  
Geoffrey Chupp ◽  
Njira L. Lugogo ◽  
Joel N. Kline ◽  
Gary T. Ferguson ◽  
Ian Hirsch ◽  
...  
Keyword(s):  
Peak Expiratory Flow ◽  
Rapid Onset ◽  
Uncontrolled Asthma ◽  
Morning Peak ◽  
Morning Peak Expiratory Flow ◽  
Expiratory Flow

Relationship between Plasma Cortisol and Peak Expiratory Flow Rate in Exercise-Induced Asthma and the Effect of Sodium Cromoglycate

1973 ◽  
Vol 45 (4) ◽  
pp. 533-541
Author(s):  
P. Jaffe ◽  
P. König ◽  
O. Ijaduola ◽  
S. Walker ◽  
S. Godfrey
Keyword(s):  
Sodium Cromoglycate ◽  
Peak Expiratory Flow ◽  
Flow Rate ◽  
Peak Expiratory Flow Rate ◽  
Plasma Cortisol ◽  
Treadmill Running ◽  
Asthmatic Patients ◽  
Control Subjects ◽  
Expiratory Flow ◽  
Exercise Induced

1. The changes in peak expiratory flow rate (PEF) and plasma cortisol were studied in relation to a 6 min period of treadmill running in six normal and eighteen asthmatic subjects. Of the asthmatics patients, five were not receiving treatment with steroids, six were receiving low doses of steroids (under 7·5 mg of prednisone daily) and seven were receiving high doses of steroids (over 7·5 mg of prednisone daily) at the time of study. 2. All subjects were studied twice within 1 week at similar times of day, once after premedication with sodium cromoglycate (SCG) and once after a placebo. 3. Resting PEF and plasma cortisol did not differ between placebo and SCG tests. 4. No change in PEF occurred as a result of exercise in the control subjects. The asthmatic patients developed post-exercise bronchoconstriction which was partly prevented by SCG but was not affected by steroids. 5. Plasma cortisol rose after exercise in the asthmatic subjects but not in the control subjects. The rise may have been related to the stress of exercise-induced asthma. SCG had no significant effect on plasma cortisol after exercise.

scholarly journals A COMPARATIVE STUDY OF YOGIC AND AYURVEDIC INTERVENTION IN THE MANAGEMENT OF TAMAKA SHWASA.

2019 ◽  
Vol 7 (5) ◽  
Author(s):  
Dr Arpan A. Bhatt ◽  
Dr Shweta Pandey ◽  
Dr Brajesh Singh ◽  
Dr Gauravi Vyas ◽  
Dr Gyanendra Datta Shukla ◽  
...  
Keyword(s):  
Peak Expiratory Flow ◽  
Flow Rate ◽  
Industrial Development ◽  
Large Scale ◽  
Intervention Group ◽  
Yoga Intervention ◽  
Asthmatic Patients ◽  
Group A ◽  
Expiratory Flow ◽  
Group B

Asthma is one of the commonest respiratory disease (as Jamnagar situated on sea coast has more moisture present in the air and polluting environment is increasing due to rapid industrial development i.e. industries using various chemicals/ pollutants, increases the incidences of Respiratory tract diseases) as well as a significant disease burden worldwide costing billions of dollars. The WHO estimates that there are between 15 and 20 million people with Asthma in India. The increase is likely to be particularly dramatic in India, which is projected to become the world’s most populous nation by 2050. An absolute 2% increase in the prevalence of Asthma in India would result in an additional 20 million people with the disease.  Anti-asthmatic drugs that are available in the market are expensive and have adverse effects. Thus, it is wise to look for an adjunct therapy to alleviate these problems. Therefore, the main aim of this study is to see the effect of Yoga on patterns of clinical features, peak expiratory flow rates and use of drugs in Asthmatic patients. Yoga intervention group (Group A) showed 70.58% reduction in the use of emergency medicine while it was 68.09% in Ayurvedic conventional group (Group B). There was a 24.93% increment in the PEFR in the Group A while only 16.49% in the Group B. There was statistically significant reduction in frequency and duration of Asthma attacks in both the Groups. Yoga exercise among Asthmatic patients resulted in a decreased number of attacks and use of drugs. It also shows significant improvement in the peak expiratory flow rate in Yoga intervention Group. Further large scale study is recommended. Keywords: Asthma, Yoga, Expiratory flow rate.

scholarly journals Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial

2001 ◽  
Vol 119 (5) ◽  
pp. 169-174 ◽  
Author(s):  
Ana Luisa Godoy Fernandes ◽  
Sonia Maria Faresin ◽  
Maria Marta Amorim ◽  
Carlos Cézar Fritscher ◽  
Carlos Alberto de Castro Pereira ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Peak Expiratory Flow ◽  
Dry Powder Inhaler ◽  
Dry Powder ◽  
Double Blind ◽  
Bronchodilator Therapy ◽  
Moderate Asthma ◽  
Morning Peak Expiratory Flow ◽  
Double Blind Clinical Trial ◽  
Inhaled Budesonide

CONTEXT: Budesonide is an inhaled corticosteroid with high topical potency and low systemic activity recommended in the treatment of chronic asthma. OBJECTIVE: This study was conducted to determine the efficacy and safety of inhaled budesonide via a breath-activated, multi-dose, dry-powder inhaler. TYPE OF STUDY: Multicenter randomized parallel-group, placebo-controlled, double-blind, clinical trial. SETTING: Multicenter study in the university units. PARTICIPANTS: Adult patients with mild-to-moderate asthma that was not controlled using bronchodilator therapy alone. PROCEDURES: Comparison of budesonide 400 µg administered twice daily via a breath-activated, multi-dose, dry-powder inhaler with placebo, in 43 adult patients (aged 15 to 78 years) with mild-to-moderate asthma (FEV1 71% of predicted normal) that was not controlled using bronchodilator therapy alone. MAIN MEASUREMENTS: Efficacy was assessed by pulmonary function tests and asthma symptom control (as perceived by the patients) and the use of rescue medication. RESULTS: Budesonide 400 µg (bid) was significantly more effective than placebo in improving morning peak expiratory flow (mean difference: 67.9 l/min; P < 0.005) and FEV1 (mean difference: 0.60 l; P < 0.005) over the 8-week treatment period. Onset of action, assessed by morning peak expiratory flow, occurred within the first two weeks of treatment. CONCLUSIONS: Budesonide via a breath-activated, multi-dose, dry-powder inhaler results in a rapid onset of asthma control, which is maintained over time and is well tolerated in adults with mild-to-moderate asthma.

Sign in / Sign up

Export Citation Format

Share Document